Dr. Michael Liss explores the critical role of the gut microbiome in cancer prevention, treatment, and overall patient wellness. Highlighting the intersection of genetics, lifestyle, and gut bacteria, he discusses how microbiome testing and personalized interventions—such as probiotics and dietary guidance—can support immunotherapy, reduce chemotherapy side effects, and optimize patient outcomes.
After being diagnosed with Stage IVa head and neck squamous cell carcinoma (HNSCC), our founder experienced firsthand the physical and biological stress that cancer and its treatments place on the body.
During treatment and recovery, careful attention was given to supporting key host-state systems, including immune balance, micronutrient pathways, metabolic health, gut microbiome stability, neurological signaling, and overall physiological resilience.
Over time, patterns began to emerge suggesting that the stability of the body’s internal environment—the host—may play an important role in how patients tolerate treatment, recover, and maintain quality of life.
Following remission, those observations became the starting point for a deeper effort: to better understand, structure, and model the supportive strategies that appeared to help preserve biological resilience during treatment.
What began as a personal investigation evolved into the foundation of a larger system. By combining clinical observations, biological modeling, longitudinal tracking, and structured data interpretation, those early insights were translated into a host-state intelligence platform and Medical Digital Twin (MDT) architecture designed to improve visibility into host-state stability over time.
Blueprint to Beat Cancer was created to bring these insights into a structured, research-driven framework that supports patients navigating cancer treatment while contributing data and understanding that may help researchers better study the role of host-state dynamics in cancer care.






